Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.55 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12852212 | 0.85 | AOC3 (0.45) | QPCTQPCTLMTNR1AMTNR1BAOC3 | |
| SCHEMBL28792657 | 0.73 | EGFR (0.42) | AOC3MAOBKDM4EALDH1A1HPGD | |
| SCHEMBL3709096 | 0.72 | QPCT (0.44) | QPCTQPCTLMTNR1AMTNR1BHTT | |
| SCHEMBL3709099 | 0.72 | QPCT (0.44) | QPCTQPCTLMTNR1AMTNR1BHTT | |
| SCHEMBL12999042 | 0.71 | QPCT (1.00) | QPCTQPCTLALDH1A1LMNAMAPT | |
| SCHEMBL12598535 | 0.70 | CASP2 (0.49) | KDM4EALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL24015869 | 0.70 | QPCT (0.51) | QPCTQPCTLMTNR1AMTNR1BHTT | |
| SCHEMBL8225111 | 0.69 | AOC3 (0.50) | AOC3MAOBKDM4EALDH1A1MAPT | |
| SCHEMBL18291413 | 0.69 | KDM4E (0.56) | MTNR1AMTNR1BKDM4EALDH1A1LMNA | |
| SCHEMBL19049443 | 0.67 | KDM4E (0.58) | QPCTQPCTLMTNR1AMTNR1BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140038968-A1 | AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS | COATS STEVEN J (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038968-A1 | AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS | COATS STEVEN J (US) | 2014-02-06 | — | — | US | disclosed |
| US-8324380-B2 | Amino-heteroaryl-containing prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-04 | — | — | US | disclosed |
| US-8324380-B2 | Amino-heteroaryl-containing prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-04 | — | — | US | disclosed |
| US-8324380-B2 | Amino-heteroaryl-containing prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-04 | — | — | US | disclosed |
| EP-2215067-A1 | AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2010-08-11 | — | — | EP | disclosed |
| US-20090163505-A1 | AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163505-A1 | AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163505-A1 | AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-25 | — | — | US | disclosed |
| WO-2009058653-A1 | AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058653-A1 | AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038968-A1 | AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS | PROKR1, PROKR2, GIPR | QPCT 487/4885QPCTL 535/4885MTNR1A 45/4885 |
| US-20090163505-A1 | AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS | PROKR1, PROKR2, GIPR | QPCT 487/4885QPCTL 535/4885MTNR1A 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.